CN110420228A - Application of the bacteroides fragilis YCH46 in the drug of preparation treatment or assisting in treating hypertension - Google Patents

Abstract

The invention relates to the application of Bacteroides fragilis YCH46 in the preparation of medicines for treating or assisting the treatment of hypertension. The present invention discovers for the first time the key role of Bacteroides fragilis YCH46 in the human intestinal tract in hypertension, and the Bacteroides fragilis YCH46 can inhibit the synthesis of intestinal corticosterone and effectively lower blood pressure. In addition, because Bacteroides fragilis YCH46 itself is a microorganism that normally exists in the intestinal tract, it will not have side effects on the body and has incomparable advantages compared to other new drugs. Utilizing the key role of Bacteroides fragilis YCH46 in hypertensive diseases in the present invention, it can be prepared into medicines, pharmaceutical compositions, food, health products or food additives, which can be used to treat essential hypertension and salt-sensitive hypertension. It has important application value in hypertensive diseases.

Description

The role of Bacteroides fragilis YCH46 in the preparation of drugs for the treatment or auxiliary treatment of hypertension application

technical field

The invention relates to the application of Bacteroides fragilis YCH46 in the preparation of medicines for treating or assisting hypertension, and belongs to the technical field of medicine.

Background technique

Hypertension (hypertension) refers to an increase in systemic arterial blood pressure (systolic and/or diastolic) as the main feature (systolic blood pressure ≥ 140 mm Hg, diastolic blood pressure ≥ 90 mm Hg), which may be accompanied by heart, brain, kidney, etc. Clinical syndrome of functional or organic damage to organs. Hypertension is one of the most common chronic diseases, and its incidence has increased rapidly in recent years. According to the 2017 U.S. Hypertension Guidelines definition (systolic blood pressure ≥130 mmHg, diastolic blood pressure ≥80 mmHg), 45.6% of Americans have high blood pressure. In my country, even according to loose standards (systolic blood pressure ≥ 140mmHg, diastolic blood pressure ≥ 90mmHg), nearly half of adults (44.7%) are hypertensive patients, while the proportion in 2014 was only 29.6%. Hypertension can cause structural dysfunction of important organs such as the heart, brain, kidney, and blood vessels, and is the most important risk factor for malignant cardiovascular and cerebrovascular events such as stroke, myocardial infarction, and heart failure.

High-salt diet is an important independent risk factor for hypertension and cardiovascular and cerebrovascular diseases. Salt-sensitive hypertension accounts for more than 60% of hypertensive patients in my country. At present, it is believed that high salt-induced salt-sensitive hypertension is mainly caused by abnormal renal water and sodium retention, increased blood volume, and increased peripheral vascular resistance. Some genetic factors (such as polymorphisms of GNB3, ADD1, and ACE) also affect the response to high salt However, the specific mechanisms causing these pathological changes have not been fully elucidated.

Activation of mineralocorticoid receptor (MR) plays an important role in the development of hypertension, especially salt-sensitive hypertension. MR is expressed in a variety of tissues including the heart, blood vessels, kidney, and intestinal epithelium, and its functions include regulation of ion and fluid transport critical for osmotic and hemodynamic homeostasis, and membrane excitation in neurons and muscle cells Sexuality, nutritional and adaptive responses to injury, and neuronal responses critical for learning, memory, and early responses to stress. Mineralocorticoid aldosterone excessively activates MR, which leads to fluid and sodium retention and induces secondary hypertension has been widely studied in recent years, while glucocorticoids cortisol and corticosterone have the same affinity for MR as aldosterone, and they can activate MR mediates abnormal sodium and potassium transport. Therefore, the abnormality of these hormone levels is closely related to the occurrence and development of hypertension. And corticosterone activates MR at basal levels in most tissues, but under normal circumstances, the inactivating effect of corticosteroid 11-β-dehydrogenase isoenzyme 2 (HSD11B2) produces a pre-receptor mechanism that makes Aldosterone becomes the main MR ligand in the body, and in some pathological conditions, the reduction of the inactivation effect of HSD11B2 on corticosterone makes corticosterone activate MR to mediate downstream biological responses. In addition to the synthesis and release of corticosterone by the adrenal gland, the thymus, brain, and intestinal epithelium can all express steroid synthase and synthesize biologically active corticosterone. The corticosterone produced by the intestinal epithelium is very low under physiological conditions, but the colon of wistar rats can synthesize a large amount of corticosterone after being given a high-salt diet, and at the same time, the serum corticosterone level is significantly increased. Serum and intestinal corticosterone were also significantly higher in hypertensive patients than in normal subjects. However, the causes of increased gut/serum corticosterone in hypertensive patients and animals are still poorly understood. In recent years, a large number of studies have shown that intestinal flora is closely related to the occurrence and development of hypertension, especially high-salt-induced hypertension, and the activation of MR is very important in high-salt-induced hypertension. Whether the gut microbiota participates in the development of hypertension by regulating the synthesis of gut-derived corticosterone deserves further study.

At present, there are more than 60 kinds of antihypertensive drugs in 15 categories, including diuretics, calcium channel blockers (CCB), β-blockers and angiotensin II receptor antagonists. There are various difficulties such as poor drug resistance, low compliance rate, large adverse drug reactions, and easy drug resistance. For example, only about 30% of the hundreds of millions of hypertensive patients in my country have received treatment, but only 7.2% of patients have achieved blood pressure control, and the global hypertension control rate is no more than 10%. Therefore, high blood pressure still causes at least 45% of heart disease deaths and 51% of stroke deaths globally every year, resulting in a loss of more than 250 billion U.S. dollars, and has become one of the most serious public health problems in the world, so it is high to develop safe and effective treatments New drugs for blood pressure loom.

Bacteroides fragilis (Bacteroides fragilis) YCH46 is a normal colonization bacterium in the human intestinal tract. There is no report on its relationship with hypertension and its effect on hypertension. See report.

Contents of the invention

Aiming at the deficiencies of the prior art, the present invention provides an application of Bacteroides fragilis YCH46 in the preparation of medicines for the treatment or auxiliary treatment of hypertension, and provides medicines, drug combinations, food, and health care products for the treatment or auxiliary treatment of hypertension. products and food additives.

Technical scheme of the present invention is as follows:

Application of Bacteroides fragilis YCH46 in preparation of medicine for treating or assisting hypertension.

According to the present invention, said Bacteroides fragilis (Bacteroides fragilis) YCH46 is a known probiotic, which is isolated from healthy human feces.

In the present invention, the Bacteroides fragilis YCH46 is isolated and cultured according to conventional technical means in the technical field.

Preferably according to the present invention, the Bacteroides fragilis YCH46 is a live Bacteroides fragilis YCH46 cell, and/or a culture supernatant of Bacteroides fragilis YCH46.

Preferably according to the present invention, the hypertension is essential hypertension or salt-sensitive hypertension.

Preferably according to the present invention, the medicine contains a pharmaceutically effective dose of Bacteroides fragilis YCH46 and a pharmaceutically acceptable carrier.

Further preferably, the pharmaceutically acceptable carrier is skimmed milk, lactose, glucose, sucrose, sorbitol, mannose, trehalose, starch, acacia, calcium phosphate, alginate, gelatin, calcium silicate, One or more of fine crystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylparaben, propylparaben, talc, magnesium stearate, or mineral oil mixture.

Preferably according to the present invention, the drug may be in any one or more pharmaceutically feasible dosage forms, including but not limited to tablets, capsules, oral liquids or lyophilized powders.

A medicine for treating or adjuvantly treating hypertension, which contains a pharmaceutically effective dose of Bacteroides fragilis YCH46.

Preferably according to the present invention, the Bacteroides fragilis YCH46 is a live Bacteroides fragilis YCH46 cell, and/or a culture supernatant of Bacteroides fragilis YCH46.

Preferably according to the present invention, the hypertension is essential hypertension or salt-sensitive hypertension.

Preferably according to the present invention, the drug may be in any one or more pharmaceutically feasible dosage forms, including but not limited to tablets, capsules, oral liquids or lyophilized powders.

A pharmaceutical composition for treating or assisting the treatment of hypertension, the pharmaceutical composition contains a pharmaceutically effective dose of Bacteroides fragilis YCH46.

Preferably according to the present invention, the Bacteroides fragilis YCH46 is a live Bacteroides fragilis YCH46 cell, and/or a culture supernatant of Bacteroides fragilis YCH46.

A food for treating or assisting the treatment of hypertension, the food contains Bacteroides fragilis YCH46.

Preferably according to the present invention, the Bacteroides fragilis YCH46 is a live Bacteroides fragilis YCH46 cell, and/or a culture supernatant of Bacteroides fragilis YCH46.

A health product for treating or assisting the treatment of high blood pressure, the health product contains Bacteroides fragilis YCH46.

Preferably according to the present invention, the Bacteroides fragilis YCH46 is a live Bacteroides fragilis YCH46 cell, and/or a culture supernatant of Bacteroides fragilis YCH46.

A food additive for treating or assisting the treatment of hypertension, the food additive contains Bacteroides fragilis YCH46.

Preferably according to the present invention, the Bacteroides fragilis YCH46 is a live Bacteroides fragilis YCH46 cell, and/or a culture supernatant of Bacteroides fragilis YCH46.

Technical characteristics and beneficial effects of the present invention

1. In the present invention, the key role of Bacteroides fragilis (Bacteroides fragilis) YCH46 in the human intestinal tract was discovered for the first time in hypertensive diseases. Bacteroides fragilis (Bacteroides fragilis) YCH46 can inhibit the colon to synthesize corticosterone and activate corticosteroids 11 - Beta-dehydrogenase isoenzyme 2 (HSD11B2), which effectively reduces the activation of the mineralocorticoid receptor (MR) by corticosterone. In addition, because Bacteroides fragilis (Bacteroides fragilis) YCH46 itself is a microorganism that normally exists in the intestinal tract, it will not have side effects on the body and has incomparable advantages over other new drugs. It is easy for patients to accept and understand the patient's response to the drug. It is expected to fundamentally achieve the effect of treating hypertension, so as to solve the problem of low compliance rate and compliance of hypertension. Moreover, Bacteroides fragilis (Bacteroides fragilis) YCH46 is easily obtained, and its amplification technology is mature, so it can be quickly put into production and obtained Highly effective preparations.

2. Utilizing the key role of Bacteroides fragilis YCH46 in hypertensive diseases in the present invention, it can be prepared in the form of medicine, pharmaceutical composition, food, health care product or food additive. The medicine, pharmaceutical composition, food, health care product or The food additive contains Bacteroides fragilis YCH46, and these drugs, pharmaceutical compositions, food, health products or food additives can be used to treat hypertension including essential hypertension and salt-sensitive hypertension, and have important application value.

Description of drawings

Figure 1 is a correlation analysis chart of intestinal microbial genus and systolic blood pressure and diastolic blood pressure; in the figure, SBP: systolic blood pressure; DBP: diastolic blood pressure; the right side is the main difference of bacteria in the control group and the HSD group in Example 1 / Latin name of the species; *: P<0.05; **: P<0.01; ***: P<0.001;

Figure 2 is a histogram of the relative abundance of five genera (Alistipes, Bacteroides, Desulfovibrio, Parabacteroides, Psychrobacter) significantly related to blood pressure in the control group (control group) and the HSD group rats; in the figure, the ordinate represents the relative abundance Abundance; **: P<0.01; ***: P<0.001;

Fig. 3 is the content diagram of Bacteroides fragilis YCH46 in the intestinal tract of the control group (control group) and HSD group; In the figure, the ordinate is the relative content of Bacteroides fragilis YCH46, Rat is a rat; Human is a person; *: P<0.05; **: P<0.01;

Figure 4 is a graph showing the effect of Bacteroides fragilis YCH46 on the synthesis of corticosterone, MR, and Hsd11b2 in the colon of C57BL/6 mice; in the figure, A is a histogram of corticosterone content in the supernatant of mouse colon tissue culture, and the ordinate is corticosterone Content, SnControl is the colon tissue culture supernatant of control group mice, SnHSD is the colon tissue culture supernatant of HSD group mice; B is the mRNA level of Mr in the mouse colon tissue; C is the mRNA level of Hsd11b2 in the mouse colon tissue; *: P<0.05; ***: P<0.001;

Fig. 5 is the broken line graph that rat blood pressure changes with raising time; Among the figure, A is the change broken line graph of rat systolic blood pressure, and ordinate SBP is systolic blood pressure; B is the change broken line graph of rat diastolic blood pressure, and ordinate DBP is Diastolic blood pressure; *: P<0.05; **: P<0.01.

Detailed ways

The technical solutions of the present invention will be further described below in conjunction with the examples, but the protection scope of the present invention is not limited thereto. Unless otherwise defined, the technical terms used in the following embodiments have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. The test reagents used in the following examples, unless otherwise specified, are conventional biochemical reagents; the experimental methods, unless otherwise specified, are conventional methods.

The hypertensive rats involved in the examples all meet the diagnostic criteria, and the blood pressure of the healthy control group is normal.

Feces and peripheral blood samples, reagent materials used and their sources in the control group and HSD group:

1. Specimen

The feces and peripheral blood used in the examples were collected from high-salt hypertensive (HSD) and normal control wistar rats. The feces used to isolate B. fragilis YCH36 were from healthy individuals.

2. Main reagent materials

Feces DNA extraction kit (Shenggong); ELISA kit (abcam company); TB green (Takara company); 3-week-old male wistar rats (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.); 8% NaCl Feed, 0.49% NaCl feed (Jiangsu Synergy Co., Ltd.); pipette tips (specifications: 10 μL, 100 μL and 1 mL), EP tubes (1.5 mL and 0.6 mL) and eight-tube tubes (0.2 mL) (Axygen); Sterile centrifuge tubes (15mL and 50mL), pipettes (5mL and 10mL) and cell culture bottles (25cm ² , 75cm ² , 150cm ² ) (Costar Company); small animal sphygmomanometer (Beijing Ruanlong Company).

The composition of M2GSC bacterial culture medium is as follows (per 1000mL system):

Peptone, 10g; Yeast extract, 2.5g; Glucose, 2.0g; Cellobiose, 2.0g; Soluble starch, 2.0g; Clarified rumen fluid, 300mL; Dipotassium hydrogen phosphate, 0.45g; g; ammonium sulfate, 0.9g; sodium chloride, 0.9g; magnesium sulfate heptahydrate, 0.09g; calcium chloride, 0.09g; resazurin, 1.0mg; deionized water, 700mL; ), 4.0g; cysteine (added after boiling), 1.0g. Finally, autoclave at 121°C for 20 minutes.

Example 1: Changes in the intestinal flora of rats in the HSD group

The feces samples of the rats in the control group and the HSD group were collected, and the total DNA in the feces was extracted by using the improved CTAB method. Universal primers were used to build the library. After the library was built, MiSeq (Illumina) was used for sequencing, and the data obtained by sequencing was analyzed using QIIME2 software. The correlation analysis results of intestinal microbial genus and systolic and diastolic blood pressure are shown in Figure 1. The results showed that Bacteroides were closely related to systolic blood pressure (SBP) and diastolic blood pressure (DBP).

Among them, the general primers of the 16s rRNA gene used for library construction are:

Upstream primers:

5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG-3',

Downstream primers:

5'GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC-3';

The relative abundance of the bacterial genera (Alistipes, Bacteroides, Desulfovibrio, Parabacteroides, Psychrobacter) closely related to blood pressure obtained from the above analysis in the control group and the HSD group rats, as shown in Figure 2, found that Bacteroides significantly related to blood pressure (Bacteroides) had the highest abundance in the two groups, and the difference was statistically significant (P<0.01), indicating that Bacteroides played a key role in the pathogenesis of hypertension.

Example 2: Isolation and cultivation of Bacteroides fragilis (Bacteroides fragilis) YCH46 in human intestine

Take 1g of fresh feces from healthy people and add it to 9mL M2GSC liquid bacterial culture medium to mix well, then use M2GSC liquid bacterial culture medium to dilute 10 concentration gradients in a 10-fold gradient, and take 0.3mL each to spread on M2GSC solid bacteria containing 1.5% agar On the culture medium, cultured at 37° C. for 48 hours in an anaerobic environment, a single colony was taken for 16s rDNA sequencing, and Bacteroides fragilis (Bacteroides fragilis) YCH46 was isolated.

In addition, the content of Bacteroides fragilis YCH46 in the feces of control group and HSD group rats, hypertensive patients and healthy people was further verified by rtPCR technology, using TB Green Premix Ex Taq (Takara) reagent in CFX96 Real-Time PCR System (Bio -Rad) for rtPCR, the detection results are shown in Figure 3, the results showed that Bacteroides fragilis YCH46 was significantly reduced in HSD group rats and hypertensive patients, which also shows that Bacteroides fragilis YCH46 is closely related to blood pressure.

Example 3: Effects of Bacteroides fragilis (Bacteroides fragilis) YCH46 on corticosterone synthesis in colon tissue cultured in vitro

Bacteroides fragilis (Bacteroides fragilis) YCH46 was amplified in M2GSC liquid bacterial culture medium at 37°C for 24 hours by anaerobic shaking to obtain Bacteroides fragilis YCH46 culture solution, which was centrifuged at 5000g for 5 minutes, and the supernatant of the culture solution was filtered out with a 0.2 μm filter B.f.S, the liquid was labeled as B.f.S; similarly, the M2GSC liquid bacterial medium was centrifuged at 5000g for 5 minutes, and the supernatant was filtered and sterilized with a 0.2 μm filter, and the liquid was labeled as M2GSC; under sterile conditions, the normal control group and high-salt induced The colonic tissue of C57BL/6 male mice in the group, each colonic tissue was fully cut up and divided into two groups, cultured in a sterile 12-well plate, DMEM medium and fetal bovine serum were added to each well, and then the control 300 μL of B.f.S and M2GSC were added to the HSD group and the HSD group respectively, cultured in the cell incubator for 12 hours, the culture medium was collected, centrifuged at 3000 g for 5 minutes, and the supernatant was taken for ELISA detection; the colon tissue was collected, and mRNA was extracted by trizol method for qPCR.

The content of corticosterone in the culture supernatant of mouse colon tissue is shown in Figure 4A. B. fragilis YCH46 culture supernatant (B.f.S) can significantly inhibit the synthesis of colon corticosterone in HSD group mice, while the control group mice colon tissue Corticosterone synthesis was not significantly affected. The mRNA expression level of Mr gene in mouse colon tissue is shown in Figure 4B. The mRNA expression level of Mr gene in the colon tissue of HSD mice cultured by M2GSC is higher, which is significantly different from that of normal control mice cultured by M2GSC (P<0.05 ), while the culture supernatant (B.f.S) of Bacteroides fragilis YCH46 significantly inhibited the mRNA expression level of Mr gene in colon tissue of HSD mice. The mRNA expression level of Hsd11b2 gene in mouse colon tissue is shown in Figure 4C, the mRNA expression level of Hsd11b2 gene in the colon tissue of HSD mice induced by high-salt diet is lower, which is significantly different from the normal control group mice cultured by M2GSC ( P<0.001), while the culture supernatant (B.f.S) of Bacteroides fragilis YCH46 could significantly increase the mRNA expression level of Hsd11b2 gene in colon tissue of mice in HSD group. The above results show that high-salt diet can significantly increase the synthesis of colonic corticosterone, increase the mRNA expression level of Mr gene, and reduce the transcription level of HSD11B2. Instead, it binds and activates MR, which in turn causes sodium and potassium transport disorders and induces hypertension. Bacteroides fragilis YCH46 can reverse the above-mentioned effects induced by high salt, and have a certain therapeutic effect on hypertension.

Embodiment 4: Effect of Bacteroides fragilis (Bacteroides fragilis) YCH46 on blood pressure of HSD group rats

Rats were fed with high-salt diet to construct high-salt hypertension (HSD) model rats. The normal control group was fed with normal rat diet, and the rats in the normal control group and the HSD group were gavaged, and MgSO ₄ was given to clean up the inherent flora the day before the gavage feeding , the rats in the HSD group were gavaged with Bacteroides fragilis YCH46 (10 ⁹ CFU/kg), and the rats in the normal control group were gavaged with normal rat diet once every other day and three times.

During the feeding process, the systolic blood pressure and diastolic blood pressure of the rats in each group were detected. The results are shown in Figure 5. The systolic blood pressure and diastolic blood pressure of the normal control group were maintained at normal levels. The HSD group not given B. fragilis YCH46 The systolic blood pressure and diastolic blood pressure of the rats remained at a high level, and the systolic blood pressure and diastolic blood pressure of the rats in the HSD group given B. fragilis YCH46 decreased significantly.

The above results indicated that B. fragilis YCH46 played a key role in the pathogenesis of hypertension. At the same time, B. fragilis YCH46 was significantly decreased in hypertensive patients and hypertensive rats induced by high-salt diet. Significantly increased in hypertensive patients and hypertensive rats induced by a high-salt diet. Bacteroides fragilis YCH46 can inhibit the high-salt diet-induced colonic corticosterone production in mice, promote the expression of HSD11B2 and reduce the level of MR. And in vivo, B. fragilis YCH46 can significantly reduce high-salt diet-induced hypertension. In summary, B. fragilis YCH46 can reduce systolic and diastolic blood pressure, and has a certain therapeutic effect on hypertension. Utilizing the key role of Bacteroides fragilis YCH46 of the present invention in hypertensive diseases, it can be prepared into the form of medicine, pharmaceutical composition, food, health product or food additive, and the medicine, pharmaceutical composition, food, health product or food additive Containing Bacteroides fragilis YCH46, these medicines, pharmaceutical compositions, foods, health products or food additives can be used for treating diseases including essential hypertension and salt-sensitive hypertension.

Claims (10)

1. Application of Bacteroides fragilis YCH46 in the preparation of medicines for treating or assisting the treatment of hypertension. 2. The application of Bacteroides fragilis YCH46 in the preparation of medicines for the treatment or auxiliary treatment of hypertension according to claim 1, characterized in that, said Bacteroides fragilis YCH46 is the live bacterium of Bacteroides fragilis YCH46, and/or fragilis Bacteroides YCH46 culture supernatant. 3. The use of Bacteroides fragilis YCH46 as claimed in claim 1 in the preparation of medicines for the treatment or auxiliary treatment of hypertension, characterized in that the hypertensive disease is essential hypertension or salt-sensitive hypertension. 4. The application of Bacteroides fragilis YCH46 as claimed in claim 1 in the preparation of medicines for the treatment or auxiliary treatment of hypertension, wherein the medicine contains a pharmaceutically effective dose of Bacteroides fragilis YCH46 and a pharmaceutically acceptable carrier wherein, the pharmaceutically acceptable carrier is skimmed milk, lactose, glucose, sucrose, sorbitol, mannose, trehalose, starch, acacia, calcium phosphate, alginate, gelatin, calcium silicate, fine A mixture of one or more of crystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylparaben, propylparaben, talc, magnesium stearate, or mineral oil . 5. The application of Bacteroides fragilis YCH46 as claimed in claim 1 in the preparation of medicines for the treatment or auxiliary treatment of hypertension, characterized in that the dosage forms of the medicines are tablets, capsules, oral liquids or freeze-dried powders. 6. A medicine for treating or assisting the treatment of hypertension, characterized in that the medicine contains a pharmaceutically effective dose of Bacteroides fragilis YCH46; wherein, the Bacteroides fragilis YCH46 is a live bacterial body of Bacteroides fragilis YCH46, and /or culture supernatant of Bacteroides fragilis YCH46; the hypertension is essential hypertension or salt-sensitive hypertension; the dosage form of the medicine is tablet, capsule, oral liquid or freeze-dried powder. 7. A pharmaceutical composition for the treatment or auxiliary treatment of hypertension, characterized in that the pharmaceutical composition contains a pharmaceutically effective dose of Bacteroides fragilis YCH46; wherein, the Bacteroides fragilis YCH46 is the live Bacteroides, and/or culture supernatant of Bacteroides fragilis YCH46. 8. A food for the treatment or auxiliary treatment of high blood pressure, characterized in that the food contains Bacteroides fragilis YCH46; wherein, the Bacteroides fragilis YCH46 is the live bacteria of Bacteroides fragilis YCH46, and/or Bacteroides fragilis YCH46 Bacillus YCH46 culture supernatant. 9. A health product for the treatment or auxiliary treatment of high blood pressure, characterized in that the health product contains Bacteroides fragilis YCH46; wherein, the Bacteroides fragilis YCH46 is a live bacterial body of Bacteroides fragilis YCH46, and/or Bacteroides fragilis YCH46 culture supernatant. 10. A food additive for treating or assisting the treatment of high blood pressure, characterized in that the food additive contains Bacteroides fragilis YCH46; wherein, the Bacteroides fragilis YCH46 is a live bacterial body of Bacteroides fragilis YCH46, and/or Bacteroides fragilis YCH46 culture supernatant.